# Recent Advances in Polyoxometalates Targeting Proteins Associated with Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Applications

## TL;DR

This review explores how polyoxometalates can target proteins linked to Alzheimer’s disease, offering new therapeutic strategies and insights for future treatments.

## Contribution

The paper systematically summarizes recent advances in POMs for Alzheimer’s, highlighting their mechanisms and therapeutic potential.

## Key findings

- POMs can inhibit Aβ aggregation and scavenge reactive oxygen species.
- They show promise in phototherapy for Alzheimer’s disease.
- Structural tunability allows precise targeting of pathogenic proteins.

## Abstract

Polyoxometalates (POMs) exhibit significant potential for application in Alzheimer’s disease (AD) therapeutics owing to their inherent chemical and physical properties and structural tunability. Through transition metal substitution, functional modification, and the construction of POMs-based nanocomposites, POMs can precisely recognize and effectively modulate various key pathogenic proteins involved in Alzheimer’s disease. They can also intervene in disease progression through multiple mechanisms, including inhibition of Aβ aggregation, disaggregation of amyloid-β (Aβ), scavenging of reactive oxygen species (ROS), hydrolytic activity, and modulation of enzyme function. In addition, due to their outstanding physicochemical properties, the application of POMs in phototherapy has emerged as a significant direction in AD treatment research. This review systematically summarizes recent advances from 2011 to 2025 in POMs targeting key pathogenic proteins in AD, comprehensively analyzes their specific mechanisms of action across different therapeutic contexts, highlights their significant advantages and broad potential in AD treatment, and provides new insights for the future structural design, functional optimization, and clinical translation of POMs.